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Factors associated with the use of 
hormone replacement therapy among 
older women 
SIR—The long-term use of postmenopausal hormone
replacement therapy (HRT) to prevent diseases has been
recently questioned by the results of the Women’s Health
Initiative [1]. The discrepancy between data provided by
observational studies and those from randomised con-
trolled trials suggests that some apparent positive associ-
ation between HRT use and long-term health beneWts
might be partially attributable to the presence of biases in
the observational studies, such as selection [2] and com-
pliance [3] biases. Data obtained in upper-middle class
women [4, 5], early postmenopausal women [6] and
women aged on average 65 years [7, 8] suggest that HRT
users are healthier and more health conscious than the
non-users. A recent study suggested a similar proWle
among older women [9], but without adjusting for the
menopause status and/or hysterectomy, two determin-
ants of HRT use [8]. The only population-based study
assessing the determinants of HRT use in older women
by taking into account the menopausal status was per-
formed in the eighties [10]. 
The aim of our study was to determine the character-
istics of HRT use among older women aged 70 or more
who participated in the Swiss Study for the Evaluation of
the Methods of Measurement of Osteoporotic Fracture
Risk (SEMOF Study). 
Popul ation and methods 
The SEMOF Study is a prospective multi-centre study
assessing the predictive value of bone ultrasound devices
for hip fractures in a cohort of 7,609 women aged 70 and
older [11, 12]. BrieXy, participants were recruited from
January 1998 to Summer 1999 from the Swiss ofWcial
population-based listings in 10 areas across the country.
We excluded those with a history of hip fracture, bilateral
hip replacement, renal failure, active cancer or dementia. 
Sociodemographic data included age, education, cur-
rent partnership situation, and previous professional sta-
tus. Clinical variables included report of previous and
current medications, menopausal status, diagnosis of
osteoporosis, personal history of hip fractures, current
alcohol consumption, cigarette smoking, and level of
physical activity. We measured weight and height to cal-
culate the body mass index (BMI). HRT use was identi-
Wed as any report of systemic (oral or transdermal
medications) oestrogen, with or without progesterone.
Current or past users were deWned as women who reported
use of HRT either at the time of the interview, or anytime
in the past. Women whose only prescribed HRT was
topical oestrogen creams were considered as never users. 
We assessed the validity of the questionnaire inform-
ation by comparing the participant’s answers with the
information provided by their primary care physician. We
randomly selected 170 participants of one centre and
asked them permission to contact their physician, and
154 women agreed (91%). One hundred and twenty-four
physicians answered the questionnaire (81% participation
rate). The agreement between the self-reported inform-
ation and the data obtained from the physician can be
deemed as either good or excellent, since the kappa stat-
istics ranged between 0.76 (diagnosis of osteoporosis)
and 0.94 (vertebral fracture) for fracture events and between
0.69 (previous calcium supplementation) and 0.94 (current
HRT use or calcium supplementation) for medication. 
We performed bivariate analyses where current users
of HRT were opposed to the others using the t-test for
continuous and the Pearson chi-square test for categor-
ical variables. The comparisons were also performed on
three categories (current, past and never) using analysis
of variance, Pearson chi-square, as well as a Wilcoxon-
type test for trend. We conducted a multivariable logistic
regression analysis of current users to adjust for potential
confounding bias. Adjusted odds ratios and 95% con-
Wdence interval are reported. Statistical analyses were
performed using STATA 7.0 statistical package. 
The ethics committee of the Swiss Academy of Med-
ical Sciences approved the study protocol. 
Results 
We included 7,609 women whose mean age (±SD) was
75.3 (±3.1) years, and mean age at menopause was 49
(±5.5) years. The vast majority (75%) reported a natural
menopause, and 22% a post-surgery menopause (mainly
due to a hysterectomy). Overall, 11% of the women
reported current and 7% past use of HRT, with an aver-
age duration of 11.3 and 5.8 years, respectively. Among
current users, the percent of women reporting unop-
posed oestrogen therapy was 27%. Current use of HRT
declined with age and BMI (Figure 1). 
As compared to never and past users, current users
experienced signiWcantly more frequently a surgical meno-
pause (38.0% versus 21.3%), were younger (mean age 74.0
versus 75.4), more likely to have a BMI lower than the
median (58.8% versus 49.1%), to live with a spouse or part-
ner (56.0% versus 49.4%), to have a high education (13.2%
versus 9.1%) and previous qualiWed professional level
(60.6% versus 50.8%), to be supplemented with calcium
(29.3% versus 19.3%) and vitamin D (19.6% versus 12.1%),
as well as to report occasional alcohol consumption (62.6%
versus 58.9%) and a diagnosis of osteoporosis (26.2% versus
17.6%). Smoking status, level of physical activity, history of
vertebral or forearm fractures, and age of menopause did
not differ between current HRT users and others. 
When we compared the distribution of these variables
among the HRT categories, we found a signiWcant linear
trend for age, BMI, diagnosis of osteoporosis, surgical
menopause, living with a spouse, professional and educa-
tional level, calcium or vitamin D supplementation, and
alcohol consumption (Table 1). Multiple logistic regression
analyses including age and all variables statistically signiW
cant with a P-value <0.20 in the bivariate analysis
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revealed that the major determinants of current use of
HRT were the following (Table 2): surgical menopause;
calcium supplementation; diagnosis of osteoporosis; high
socioeconomic status; lower weight; marital status. 
Discussion 
The proportion of current and past HRT users among
these 7,609 older women was 11 and 7%, respectively.
To our knowledge, this is the Wrst study performed dur-
ing the nineties taking into account the type of meno-
pause and reporting the prevalence of HRT use and the
health proWle of the HRT users in older women. 
After adjustment for age, the major determinant for
the use of HRT was a post-surgery menopause, which
extends a similar association in younger women [8]. The
current HRT users were different from former and never
users with regard to disease prevention measures. After
taking into account age, the report of post surgery meno-
pause and the diagnosis of osteoporosis, current HRT
users appear to be more likely to have a ‘health con-
scious’ proWle (i.e., to be thinner and more likely to have
calcium supplementation) and a higher socioeconomic
status. The signiWcant trends for several determinants in
never, former, and current users, suggest that the more a
woman is health conscious and has a high socioeconomic
status, the more likely she is to keep on using HRT. Our
results are in concordance with data obtained during the
eighties [10, 13, 14]. These results extend data obtained in
younger women [6–9, 13] and in older women but
Figure 1. Use of hormone replacement therapy among women aged 70 and older by body mass index (kg/m2). The areas of
the symbols are proportional to the size of the population at that speciWc BMI.
Table 1. Analysis of the association between various factors and the use of hormone replacement therapy (n = 7,609) 
aBMI = body mass index (weight – kg/height2 – cm). 
bHigh education = having a university or equivalent degree (versus lower education level). 
cJob requiring any form of training, such as apprenticeship or college (versus unqualiWed job). 
dAny alcohol consumption = any level of consumption, i.e. occasional or regular (versus no drink at all). 
eNo sedentary lifestyle = any lifestyle or sports activities (versus no activity at all). 
 
Factors 
Current 
(n = 841) 
Past 
(n = 533) 
Never 
(n = 6235) P-value P for trend
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (mean ± SD), year 74.0 ± 2.9 74.4 ± 2.9 75.5 ± 3.0 <0.001 <0.001 
BMIa (mean ± SD), kg/m2 24.9 ± 3.8 25.5 ± 4.0 26.1 ± 4.5 <0.001 <0.001 
BMIa <25.5 kg/m2, % 58.8 54.4 48.5 <0.001 <0.001 
Living with a spouse, % 56.0 54.6 48.9 <0.01 <0.01 
High educationb, % 13.2 11.8 8.9 <0.001 <0.001 
Previous qualiWed jobc, % 60.6 57.0 50.3 <0.001 <0.001 
Post-surgery menopause, % 38.0 29.7 20.4 <0.001 <0.001 
Diagnosis of osteoporosis, % 26.2 23.6 17.1 <0.001 <0.001 
Ca supplementation, % 29.3 25.0 18.8 <0.001 <0.001 
Vitamin D supplementation, % 19.6 17.7 11.6 <0.001 <0.001 
Any alcohol consumptiond, % 62.6 67.3 58.1 <0.001 <0.001 
No sedentary lifestylee, % 25.3 25.5 27.1 NS – 
No current smoking, % 91.6 93.4 92.0 NS – 
Any fracture in the past, % 53.0 54.2 51.0 NS – 
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without control for previous hysterectomy [13]. Such a
‘health-conscious’ proWle has also been demonstrated in
other preventive medicine areas [15]. 
Why this difference regarding health consciousness
between current, past and never older HRT users? A self-
selection by the women themselves is possible; the
women with a health conscious proWle might either have
asked their physicians for or were compliant with HRT
more frequently than other women. Current HRT users
have been recently shown more likely to be worried
about becoming less attractive, suggesting that they may
have asked for or were compliant with HRT because of
their desire to feel and look younger [8]. It is also possible
that physicians themselves selected among their patients
the candidates for such therapy according to their life-
style, current medications or socioeconomic status. Our
data support the recommendations to share with the
patient the pros and cons of HRT before prescribing this
therapy to a postmenopausal woman [16]. 
We compared the distribution of some variables with
data in the age-matched Swiss general population pro-
vided by the Swiss Health Survey [17]. The prevalence of
smoking (8% versus 7%, respectively) and of hysterec-
tomy (23% versus 21%) and the median BMI (25.5 versus
25.2 kg/m2) were similar. These comparisons indicate
that our study population are not different from the
source population. Furthermore, the age at the meno-
pause and the proportion of natural menopause were
concordant with previous data [18, 19]. 
Our study has limitations. First, we used self-reported
data. However, the very good agreement between the report
of the medications (including HRT use) and the history of
fractures, and the data provided by the participant’s phys-
ician give credence to the validity of our data. The validity of
information on medications and fractures has also been pre-
viously demonstrated [20–25]. Second, a recall bias is poss-
ible [26]. However, we did not Wnd any differences between
HRT users and the other women in their proportion to
report other events, such as previous fractures. 
We conclude that older women using HRT had more
often a post-surgery menopause and a diagnosis of oste-
oporosis. Besides, they were more likely to have a ‘health
conscious’ proWle, as well as to have a high socioeco-
nomic status, than non-users. 
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